Azithromycin-d3
(Synonyms: 阿奇霉素 13C-d3) 目录号 : GC46903An internal standard for the quantification of azithromycin
Cas No.:163921-65-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Azithromycin-d3 is intended for use as an internal standard for the quantification of azithromycin by GC- or LC-MS. Azithromycin is a macrolide antibiotic.1 It is active against S. pneumoniae, S. aureus, N. gonorrhoeae, M. pneumoniae, H. pylori, C. trachomatis, and H. influenzae in vitro (MIC90s = <0.01-2 mg/L). Azithromycin increases survival in mouse models of intraperitoneal S. pyogenes, S. pneumoniae, E. faecalis, or H. influenzae infection (ED50s = 0.78, 8.7, 12.7, and 30.3 mg/kg, respectively).2 It also decreases plasma levels of IL-6, TNF-α, and IL-1β and increases survival in mouse model of LPS-induced sepsis when administered at a dose of 100 mg/kg.3 Formulations containing azithromycin have been used in the treatment of a variety of bacterial infections.
1.Kanatani, M.S., and Guglielmo, B.J.The new macrolides. Azithromycin and clarithromycinWestern J. Med.160(1)31-37(1994) 2.Girard, D., Finegan, S.M., Dunne, M.W., et al.Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection modelsJ. Antimicrob. Chemother.56(2)365-371(2005) 3.Patel, A., Joseph, J., Periasamy, H., et al.Azithromycin in combination with ceftriaxone reduces systemic inflammation and provides survival benefit in a murine model of polymicrobial sepsisAntimicrob. Agents Chemother.62(9)e00752-00718(2018)
Cas No. | 163921-65-1 | SDF | |
别名 | 阿奇霉素 13C-d3 | ||
Canonical SMILES | C[C@@H]([C@@H]([C@H](C(O[C@H](CC)[C@@](C)(O)[C@H](O)[C@H]1C)=O)C)O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@@]2(C)OC)[C@H]([C@](O)(C[C@H](CN1C([2H])([2H])[2H])C)C)O[C@@](O[C@H](C)C[C@@H]3N(C)C)([H])[C@@H]3O | ||
分子式 | C38H69D3N2O12 | 分子量 | 752 |
溶解度 | DMSO: 100 mg/ml,Ethanol: 100 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.3298 mL | 6.6489 mL | 13.2979 mL |
5 mM | 0.266 mL | 1.3298 mL | 2.6596 mL |
10 mM | 0.133 mL | 0.6649 mL | 1.3298 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
A LC-MS/MS validated method for determination of azithromycin in human tears and its application to an ocular pharmacokinetic study
Pharmazie 2020 Oct 1;75(10):478-482.PMID:33305720DOI:10.1691/ph.2020.0538
A rapid and sensitive method for the quantitative analysis of azithromycin in human tears by LC-MS/MS was developed and validated. Following extraction from collected Schirmer tear strips by methanol-water (4:1, v/v), the analyte and IS (Azithromycin-d3) were separated on a Waters Atlantis™ dC18 column (2.1 mm × 30 mm, 3 μm) by gradient elution with 0.1% (v/v) formic acid in methanol-water (1:9) and methanol-acetonitrile (9:1) as the mobile phase. Electrospray ionization in positive ion mode and MRM were used to monitor the ion transitions at m/z 749.6 → 591.6 (azithromycin) and 752.4 → 594.4 (Azithromycin-d3). The results indicated that the method had excellent sensitivity and specificity. The analyte appeared to have good linearity in the range of 5-1000 ng/ mL. Both the intra-batch and inter-batch precisions (in terms of RSD) were <10%, and the accuracies (in terms of RE) were within ±15%. The lower limit of quantification, matrix effect, extraction recovery, stability and dilution integrity were also evaluated and satisfied the validation criteria. Artificial tears served as the surrogate matrix, and no matrix difference was found when compared with that of real human tears. Finally, this method was successfully applied in an ocular pharmacokinetic study in healthy volunteers following instillation of azithromycin eyedrops.